Fulcrum Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Alexander C. Sapir
- Full Time Employees
- 9
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 26 Landsdowne Street Cambridge MA United States of America 02139
- IPO Date
- Jul 18, 2019
- CIK
- 0001680581
- Website
- fulcrumtx.com
- Similar Companies
- Business
- Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics that modulate gene expression to treat genetically defined rare diseases. The company’s product portfolio includes its lead candidate, pociredir, an oral fetal hemoglobin inducer in Phase 1b clinical trials for the treatment of sickle cell disease (SCD) and beta-thalassemia. Fulcrum also develops losmapimod, an oral small molecule for facioscapulohumeral muscular dystrophy (FSHD). The company is advancing additional early-stage programs targeting bone marrow failure syndromes including Diamond-Blackfan anemia, 5q deletion syndrome, Shwachman-Diamond syndrome, and Fanconi anemia. Fulcrum’s drug candidates aim to address the root genetic causes of these diseases through gene expression modulation. Founded in 2016 and headquartered in Cambridge, Massachusetts, Fulcrum operates primarily in the United States but has established a significant global partnership with Sanofi for the development and commercialization of losmapimod outside the U.S. This strategic alliance, formed in 2024, includes an upfront payment of $80 million to Fulcrum and potential milestone payments over $975 million, with shared global development costs and tiered royalties. Fulcrum retains U.S. commercialization rights while leveraging Sanofi’s global commercial infrastructure for markets beyond the U.S. Recent company developments include promising clinical results announced in 2025 from the Phase 1b PIONEER trial of pociredir, showing dose-dependent increases in fetal hemoglobin with good safety and tolerability profiles, positioning pociredir as a potential transformative once-daily oral therapy for SCD. Enrollment for a higher-dose cohort has been completed with data expected by year-end 2025. Fulcrum is also preparing to submit an investigational new drug application (IND) in late 2025 for its programs targeting bone marrow failure syndromes. The company ended the third quarter of 2025 with over $200 million in cash, ensuring operational stability through 2028. Fulcrum’s core business segments encompass rare genetic and neuromuscular diseases, with an emphasis on developing disease-modifying therapies through precision small molecule approaches. Its pipeline reflects a focus on rare diseases with high unmet medical need, leveraging proprietary technology to identify targets for gene expression modulation and provide meaningful clinical benefits. This comprehensive approach positions Fulcrum Therapeutics as a specialized biopharmaceutical innovator advancing treatments for genetically defined rare diseases with a robust clinical pipeline and strategic global partnerships driving its commercialization efforts.
Company News
Kaplan Fox Advises Investors of Fulcrum Therapeutics, Inc. (FULC) to Contact the Firm Regarding a Securities Investigation
BlackRock Inc. Acquires Shares of 8,824,259 Fulcrum Therapeutics, Inc. $FULC
Kaplan Fox Notifies Investors of Fulcrum Therapeutics, Inc. (FULC) of a Securities Law Investigation
Are UTZ, VCTR, FULC, CZR Obtaining Fair Deals for their Shareholders?
Kaplan Fox Encourages Fulcrum Therapeutics, Inc. (FULC) Investors to Contact the Firm Regarding a Securities Investigation
Kaplan Fox Alerts Investors of Fulcrum Therapeutics, Inc. (FULC) to a Securities Law Investigation
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)
Kaplan Fox Announces an Investigation into Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC
Halper Sadeh LLC is Investigating Whether WEAV and FULC are Obtaining Fair Deals for their Shareholders
Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc. - FULC
Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc. - FULC
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) to Contact the Firm to Learn About Their Legal Rights
Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal
Are MITT, ARX, HHS, FULC Obtaining Fair Deals for their Shareholders?
Are MITT, ARX, HHS, FULC Obtaining Fair Deals for their Shareholders?
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) for Potential Violations of the Federal Securities Laws
Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal